Acronym:
Harmony GO29833
ACTRN/NCT /ethics:
Scientific title:
A Phase Ib/II Study Evaluating the Safety and Efficacy of MPDL3280A in combination with either Obinutuzumab plus bendamustine or Obinutuzumab plus chop in patients with follicular lymphoma or diffuse large B-cell lymphoma
Summary of trial and patient characteristics
| Cancer Type | Lymphoma | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase I, Phase II | Tumour Stream | Lymphoma |
| Age Range | 18 years and older | Cancer Stage | Locally Recurrent or Locally Advanced |
| Sex | Both | Anticipated Start Date | |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Lymphoma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I, Phase II |
| Age Range | 18 years and older |
| Sex | Both |
| Molecular Target | |
| Tumour Stream | Lymphoma |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | |
| Anticipated End Date |
Trial Summary
A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with polatuzumab vedotin and ventoclax in patietns with relpased or refractory follicular lymphoma and Rituximab in combination with Polatuzumab Vedotin and Ventoclax in patietns with relapsed or refractory diffuse large B-cell lymphoma
Lay Summary
A Phase Ib/II Study Evaluating the Safety and Efficacy of MPDL3280A in combination with either Obinutuzumab plus bendamustine or Obinutuzumab plus chop in patients with follicular lymphoma or diffuse large B-cell lymphoma
Sponsor / Cooperative group
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Queen Elizabeth Hospital | Sue Yeend | Sue.Yeend@sa.gov.au | 08 8222 6148 | U Hahn | Recruitment on Hold |